BUND FINANCE

BUND FINANCE › Stocks › EW

Edwards Lifesciences Corporation (EW)

NYSE · Stock price, chart and technical analysis

US$105.23-0.2000 (-0.19%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$105.43
OpenUS$104.74
Day rangeUS$103.07 – US$106.56
52-week rangeUS$74.66 – US$108.00
Market capUS$60.51B
Volume3.92M
50-day averageUS$91.14
200-day averageUS$86.58
Beta0.83

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$5.2BUS$5.4BUS$5.0BUS$5.4BUS$6.1B
Net incomeUS$1.5BUS$1.5BUS$1.4BUS$4.2BUS$1.1B
EPS (diluted)2.382.442.306.971.83
Gross margin76.6%78.3%79.3%79.5%78.1%
Operating margin30.8%31.6%28.5%25.4%27.0%
Net margin28.7%28.3%28.0%76.8%17.7%
Free cash flowUS$1.4BUS$953.4MUS$629.5MUS$289.9MUS$1.3B
Total debtUS$690.3MUS$691.3MUS$685.1MUS$700.0MUS$705.4M
CashUS$862.8MUS$769.0MUS$1.1BUS$3.0BUS$2.9B

Compound annual growth: revenue 3.8% · net income -8.1% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E59.5x34.8x27.1x
EV / EBITDA35.3x30.9x16.5x
Operating margin25.5%—3.6%
Net margin15.3%—-0.0%
Debt / equity0.29—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Edwards Lifesciences Corporation

SectorHealthcare
IndustryMedical - Devices
CountryUS
CEOBernard J. Zovighian
Employees16,000
IPO date2000-03-27

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they…

www.edwards.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice